Syngenta Chief Executive Officer Erik Fyrwald sees the imminent $43 billion Chinese takeover of the Swiss company as a timely moment to gain a powerful benefactor just as a host of antitrust reviews trigger an abundance of acquisition opportunities.
The next few years will see billions of dollars in acquisition opportunities, and Fyrwald said he’s interested in looking at assets that could come to market as part of a tie-up between Bayer and Monsanto, as this opportunity won’t come around again.
“The majors will have consolidated, so I think in the future there’ll be more bolt-on-type deals of smaller companies that fill gaps where there are fewer overlaps and competitive concerns,” Fyrwald said in an interview in Brussels on Monday. China National Chemical is in the final stages of acquiring Syngenta.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI